The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|December 19, 2022
Rheumatoid Arthritis Quiz: Discontinuing DMARDs
Author(s)Ingrid Torjesen
What does the American College of Rheumatology recommend regarding discontinuing DMARD therapy in patients with rheumatoid arthritis? Test your knowledge with this quiz.
Advertisement
Is the following statement true or false?
The American College of Rheumatology recommends against discontinuation of all disease-modifying antirheumatic drugs (DMARDs).
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement